Publication date: Aug 13, 2019
Amplion, a startup that helps healthcare companies sort through biological data, closed a Series A fundraising round led by Greycroft with participation from existing investors Revolution’s Rise of the Rest Seed Fund and Imagen Capital Partners.
-Every week there are thousands of clinical trials as well as research articles being published,” said Dr. Amanda Enstrom, chief product officer at Amplion.
Amplion’s core product, called Biomarkerbase, combs through information published to resources such as ClinicalTrials. org or PubMed. gov and identifies therapeutically important biomarkers, which are molecules that indicate diseases and other biological states.
Amplion was co-founded by chief technology officer Adam Carroll and John Audette, who left the company in 2016.
- Venture capital investment in AI and mental health startups surges in Q2: report
- Technology and Toys Panel – 2019 Stanford Medicine Big Data | Precision Health
- Google AI on Track to Revolutionize Medicine
- Technologies like blockchain have potential to ensure transparency in medicine supply chain: Experts
- How Precision Medicine Could Boost Chronic Disease Management
- The US Precision Medicine Initiative
- Syapse Announces Collaboration with Pfizer in Oncology Precision Medicine Focused on Outcomes Research Using Real-World Evidence
- Parkinson’s Foundation launches free genetic testing initiative to advance precision medicine
- Physician viewpoint: Precision medicine is a ‘great deal,’ regardless of cost
- Big Data vs. Big Disease: How Algorithms Can Stop Pandemics | Wendy Taylor